Neurontin Articles
Depomed shares plummet as Ph III Serada trial fails one endpoint
17 October 2011
Clinical study of epilepsy drug may have served primarily to promote drug and increase prescribing
28 June 2011
Teva and Pfizer settle over Neurontin; France drops Champix; Actavis’ Aricept generic cleared
1 June 2011
Jury finds against Pfizer, calling for $142M in damages for drug fraud; Teva gets tentative OK for generic Argatroban
26 March 2010
GlaxoSmithKline/XenoPort get negative response from USA’s FDA for Horizant; Merck & Co won’t file for vicriviroc now
18 February 2010
Neuropathic pain - brighter future for pipeline drugs with market to double in value to $5.2 billion
17 February 2010
Japanese filing of gabapentin enacarbil for RLS triggers $5 million milestone from Astellas to XenoPort
20 November 2009
Pfizer disputes NEJM findings of skewing data on Neurontin
12 November 2009
Public Citizen’s HRG slams Pfizer’s $2.3 billion settlement as not enough to deter bad behaviour by Pharma
9 September 2009
GSK/Xenoport drug fails Ph II DPN study
28 April 2009
French pharmacy sales up only 1.8% in 2008
6 April 2009
NDA acceptance triggers $23M fee to XenoPort
23 March 2009
XenoPort swings into loss of $62.5M in 2008
2 March 2009
GSK/XenoPort resubmit NDA in RLS
19 January 2009
Anti-epileptics to get suicide warnings in USA
22 December 2008
GSK/XenoPort withdraw Solzira filing
17 November 2008
Pfizer denies Neurontin data was "manipulated"
13 October 2008
GSK/XenoPort submit NDA for Solzira
22 September 2008
Role for Neurontin in alcohol dependence?
9 June 2008
GSK's RLS drug is well-tolerated
28 April 2008
Ranbaxy issues first Indian drug recall in USA
26 November 2007
Neurontin ruling overturned by US court
1 October 2007
13 new drugs added to Japan's NHI list
18 September 2006
Israeli basket update c'tee recommends another 16 new technologies
4 September 2006
US drugmaker critics' challenged over conflict of interest
28 August 2006
Pfizer's gabapentin OK for Japan manufacture
14 August 2006
Japan stock market week to Dec 5
12 December 2005
XenoPort licenses XP13512 to Astellas
12 December 2005
Stock Commentary - New York week to Aug 15
5 September 2005
US orphan status for TheraQuest's TQ-1017
22 August 2005
Stock Commentary - New York
15 August 2005
Alpharma sees 21% 1st-qtr income rise
23 May 2005
Alpharma announces 2004 EPS of $0.56
11 April 2005
IVAX launches gabapentin in USA
4 April 2005
IVAX launches gabapentin in USA
4 April 2005
IVAX announces record sales in 2004
28 March 2005
Pfizer's Lyrica cuts seizure rate in half
21 February 2005
Teva's 4th-qtr income soars 40%
21 February 2005
Alpharma settles gabapentin exclusivity litigation
21 February 2005
Alpharma posts 3rd-qtr loss on legal settlements, write-offs
8 November 2004
UK NICE OKs Novartis' Gleevec as first-line GIST management, also views epilepsy care
8 November 2004
Gabapentin injunction hearing rescheduled
11 October 2004
Pfizer files for preliminary gabapentin injunction
4 October 2004
Alpharma files to remove stay on gabapentin launch
20 September 2004
Neuropathic pain mkt "to reach $4.83B by 2010"
13 September 2004
FDA gives Pfizer's Lyrica mixed response
13 September 2004
Pfizer fails to stop IVAX' generic Neurontin
30 August 2004
Florida curbs off-label use of five Rx drugs
16 August 2004
Pfizer reaches $430M Nuerontin settlement
24 May 2004
Stock Commentary - New York
24 May 2004
UK NICE guidance on insomnia drugs
10 May 2004
Stock Commentary - New York
10 May 2004
UK NICE backs newer antiepileptics
29 March 2004
Parke-Davis case
16 February 2004
Litigation fears hit off-label CNS Rxing
15 December 2003
FDA issues tentative OK for Teva generic
27 October 2003
Janssen-Cilag's topiramate expected to grow migraine prevention market
29 September 2003
Depomed gets exclusive gabapentin rights
29 September 2003
Stock Commentary - New York
22 September 2003
Alpharma surges as FDA approves generic
22 September 2003
Teva gets tentative FDA OK for generic gabapentin
18 August 2003
Stock Commentary - New York
18 August 2003
Alpharma wins Pfizer patent dispute
16 June 2003
Colorado Medicaid sets eight-drug limit
5 May 2003
Stock Commentary - New York
31 March 2003
Pfizer, P-D sued over off-label Neurontin
17 February 2003
IVAX also claims gabapentin exclusivity
10 February 2003
Purepac gets US exclusivity for gabapentin generic
3 February 2003
Pfizer says gabapentin ruling has "no bearing"
27 January 2003
Teva gabapentin ANDA
29 July 2002
IVAX wins generic approvals in Poland
8 July 2002
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
